Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2023 Jan 5;13:1116575. doi: 10.3389/fphar.2022.1116575

Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine

Gianluca Dini 1,*, Eleonora Tulli 1, Giovanni Battista Dell’Isola 1, Elisabetta Mencaroni 1, Giuseppe Di Cara 1, Pasquale Striano 2,3, Alberto Verrotti 1
PMCID: PMC9851158  PMID: 36686669

In the published article, there was an error. The conclusions of the article should be more cautionary and provide a more objective stance on the benefits and risks of this drug and its use. As such, a correction has been made to the Conclusion, final sentence. The original sentence reads as follows: “FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, pointing out that significant benefits outweigh potential cardiac risks.”

The corrected sentence appears below: “FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, suggesting that benefits might outweigh potential cardiac risks, although this will need to be established in targeted investigations.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES